je.st
news
Tag: regeneron pharmaceuticals
Regeneron Pharmaceuticals Is My Top Pick In The Biotech Space
2016-04-03 03:15:32| Biotech - Topix.net
The shares have sold off in sympathy with the meltdown in the biotech sector, with one caveat that REGN has the best near-term pipeline in the business. Based on the strength of the near-term pipeline, I added shares as detailed to subscribers on the 13th of March.
Regeneron Pharmaceuticals Rating Reiterated by Piper Jaffray
2015-10-04 23:23:38| Biotech - Topix.net
's stock had its "hold" rating restated by stock analysts at Piper Jaffray in a research report issued to clients and investors on Sunday, Analyst Ratings.Net reports. Shares of Regeneron Pharmaceuticals traded up 1.29% during trading on Friday, reaching $479.07.
Tags: rating
pharmaceuticals
piper
jaffray
Regeneron Pharmaceuticals major shareholder Sanofi Acquires 147,209 Shares
2015-09-27 09:48:03| Apparel - Topix.net
Regeneron Pharmaceuticals major shareholder Sanofi bought 147,209 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 23rd. The shares were bought at an average cost of $534.67 per share, with a total value of $78,708,236.03.
Tags: major
shares
shareholder
pharmaceuticals
Regeneron Pharmaceuticals: 2 More Factors That Could Boost Stock Price
2015-08-06 12:47:38| Biotech - Topix.net
The company is moving closer to a stage where it might consider returning some cash to shareholders, which will boost returns. Regeneron Pharmaceuticals shares rose to an all-time high level on Tuesday as the company reported solid results for the second quarter and raised its revenue guidance for the full year.
Tags: price
stock
factors
boost
Regeneron Pharmaceuticals Given "Outperform" Rating at RBC Capital
2015-06-06 21:12:59| Biotech - Topix.net
REGN has been the subject of a number of other recent research reports. Analysts at Piper Jaffray reiterated a "neutral" rating and set a $484.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 21st.
Tags: rating
capital
pharmaceuticals
rbc